Oral supplementation with branched-chain amino acids (BCAA) in liver cirrhotic patients suppressed the expression of EP300 and decreased the incidence of HCC [38] that agree with the differential expression of EP300 among the study groups. Here, EP300 is linked to hepatocellular carcinoma.